All Dr Thomas Cornell (Protein Engineering - Abzena) articles
-
ArticleWhy most T-cell engagers fail - and how to fix it
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.